发明名称 Heterobicyclic sphingosine 1-phosphate analogs
摘要 Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.
申请公布号 US9181191(B2) 申请公布日期 2015.11.10
申请号 US201213646143 申请日期 2012.10.05
申请人 BIOGEN MA INC. 发明人 Caldwell Richard D.;Guckian Kevin M.;Kumaravel Gnanasambandam;Lee Wen-Cherng;Lin Edward Yin-Shiang;Liu Xiaogao;Ma Bin;Scott Daniel M.;Shi Zhan;Thomas Jermaine;Taveras Arthur G.;Zheng Guo Zhu
分类号 A61K31/47;C07D215/20;C07C217/74;C07D215/06;C07D215/227;C07D233/32;C07D239/74;C07D277/64;C07D401/04;C07F9/09;C07F9/60;C07F9/6512;C07F9/6574 主分类号 A61K31/47
代理机构 McCarter & English, LLP 代理人 McCarter & English, LLP ;Davis Steven G.;Zhang Xin
主权项 1. A compound of formula (I):wherein: A1 is —C(X1)═; A2 is —C(X2)═; A3 is —N═; A4 is —C(X4)═; A5 is —C(X5)═; A6 is —C(X6)═; X1 is hydrogen, halo, hydroxy, nitro, cyano, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxy, haloalkoxy, cycloalkoxy, halocycloalkoxy, acyl, aminoacyl, —NRfRg, —N(Rf)SO2Rg, —SO2Rf, —SO2NRfRg, —CO2Rf, trialkylamino, aryl, or heteroaryl; X2 is hydrogen, halo, hydroxy, nitro, cyano, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxy, haloalkoxy, cycloalkoxy, halocycloalkoxy, acyl, aminoacyl, —NRfRg, —N(Rf)SO2Rg, —SO2Rf, —SO2NRfRg, —CO2Rf, trialkylamino, aryl, or heteroaryl; X4 is hydrogen, halo, hydroxy, nitro, cyano, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxy, haloalkoxy, cycloalkoxy, halocycloalkoxy, acyl, aminoacyl, —NRfRg, —N(Rf)SO2Rg, —SO2Rf, —SO2NRfRg, —CO2Rf, trialkylamino, aryl, or heteroaryl; X5 is hydrogen, halo, hydroxy, nitro, cyano, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxy, haloalkoxy, cycloalkoxy, halocycloalkoxy, acyl, aminoacyl, —NRfRg, —N(Rf)SO2Rg, —SO2Rf, —SO2NRfRg, —CO2Rf, trialkylamino, aryl, or heteroaryl; X6 is hydrogen, halo, hydroxy, nitro, cyano, alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxy, haloalkoxy, cycloalkoxy, halocycloalkoxy, acyl, aminoacyl, —NRfRg, —N(Rf)SO2Rg, —SO2Rf, —SO2NRfRg, —CO2Rf, trialkylamino, aryl, or heteroaryl; Y is —ORf, —(CRfRg)ORf, —(CRfRg)2ORf, —O—P(O)(ORf)ORg, —OC(O)Rc, —C(O)ORc, —(CRfRg)—P(O)(ORf)ORg, —(C(OH)Rf)—P(O)(ORf)ORg, —S—P(O)(ORf)ORg, tetrazole, —SO2NHRf, —SO3, —CONHRf, —Si(OH)2, or —B(OH)2; W is —CRfRg—, —NRf—, —O—, —S—, —SO—, or —SO2—; Cy is cycloalkyl, cycloalkenyl, heterocyclyl, aryl, or heteroaryl; wherein Cy is optionally substituted by 1-6 substituents selected from the group consisting of hydrogen, halo, hydroxy, nitro, cyano, —NRfRg, alkyl, haloalkyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkenylalkyl, heterocyclylalkyl, arylalkyl, heteroarylalkyl, alkoxy, haloalkoxy, cycloalkylalkoxy, cycloalkenylalkoxy, heterocyclylalkoxy, aryloxy, arylalkoxy, heteroaryloxy, heteroarylalkoxy, acyl, cycloalkylacyl, cycloalkenylacyl, heterocyclylacyl, arylacyl, heteroarylacyl, thioalkyl, alkenyl, alkynyl, cycloalkenyl, heterocyclyl, aryl, and heteroaryl; L1 is —CH2—, —CHF—, or —CF2—; Z4 is hydrogen, halo, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, or —ORf; or Z4 is —CH2— bound to the carbon atom to which Y is bound; or L1, Z4, Y, and the atoms to which they are bound form a 4-7 membered cycloalkyl group or a 4-7 membered heterocyclyl group having 1 or 2 heteroatoms selected from O and N; Ra is hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, or heterocyclyl; wherein each of alkyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl and heterocycle are optionally substituted with 1 to 5 substituents independently selected from the group consisting of halo, oxo, —CN, —CHO, —CF3, —OH, —NO2, alkyl, —OCF3, alkoxy, cycloalkoxy, cycloalkenoxy, amino, alkylamino, dialkylamino, acylamino, aminoacyl, alkylsulfonyl, alkylaminosulfonyl, and dialkylamino sulfonyl; Rb is hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, or heterocyclyl; wherein each of alkyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl and heterocycle are optionally substituted with 1 to 5 substituents independently selected from the group consisting of halo, oxo, —CN, —CHO, —CF3, —OH, —NO2, alkyl, —OCF3, alkoxy, cycloalkoxy, cycloalkenoxy, amino, alkylamino, dialkylamino, acylamino, aminoacyl, alkylsulfonyl, alkylaminosulfonyl, and dialkylaminosulfonyl; or Rb and Z4 are taken to together to form —C(O)O— or ═C(Rf)O—; Rc is alkyl, aryl, trifluoromethyl, methylsulfonyl, trifluoromethylsulfonyl, p-tolylsulfonyl, or a group selected such that —OCORc is a good leaving group; each Rf, independently, is hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, or heterocyclyl; wherein each of alkyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl and heterocycle are optionally substituted with 1 to 5 substituents independently selected from the group consisting of halo, oxo, —CN, —CHO, —CF3, —OH, —NO2, alkyl, —OCF3, alkoxy, cycloalkoxy, cycloalkenoxy, amino, alkylamino, dialkylamino, acylamino, aminoacyl, alkylsulfonyl, alkylaminosulfonyl, and dialkylaminosulfonyl; each Rg, independently, is hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, or heterocyclyl; wherein each of alkyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl and heterocycle are optionally substituted with 1 to 5 substituents independently selected from the group consisting of halo, oxo, —CN, —CHO, —CF3, —OH, —NO2, alkyl, —OCF3, alkoxy, cycloalkoxy, cycloalkenoxy, amino, alkylamino, dialkylamino, acylamino, aminoacyl, alkylsulfonyl, alkylaminosulfonyl, and dialkylaminosulfonyl; or a pharmaceutically acceptable salt thereof.
地址 Cambridge MA US